[go: up one dir, main page]

WO2007002571A3 - Use of an anti c5 complement antibody to treat patients with sickle cell disease - Google Patents

Use of an anti c5 complement antibody to treat patients with sickle cell disease Download PDF

Info

Publication number
WO2007002571A3
WO2007002571A3 PCT/US2006/024770 US2006024770W WO2007002571A3 WO 2007002571 A3 WO2007002571 A3 WO 2007002571A3 US 2006024770 W US2006024770 W US 2006024770W WO 2007002571 A3 WO2007002571 A3 WO 2007002571A3
Authority
WO
WIPO (PCT)
Prior art keywords
sickle cell
cell disease
treat patients
complement antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/024770
Other languages
French (fr)
Other versions
WO2007002571A2 (en
Inventor
Russell Rother
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of WO2007002571A2 publication Critical patent/WO2007002571A2/en
Publication of WO2007002571A3 publication Critical patent/WO2007002571A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A method of treating a sickle cell patient with an anti C5 complement antibody is disclosed. Treatment with said antibody decreases the extent of red blood cell lysis and decreases the consequential clinical sequelae.
PCT/US2006/024770 2005-06-23 2006-06-23 Use of an anti c5 complement antibody to treat patients with sickle cell disease Ceased WO2007002571A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69347305P 2005-06-23 2005-06-23
US60/693,473 2005-06-23

Publications (2)

Publication Number Publication Date
WO2007002571A2 WO2007002571A2 (en) 2007-01-04
WO2007002571A3 true WO2007002571A3 (en) 2007-05-03

Family

ID=37595940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/024770 Ceased WO2007002571A2 (en) 2005-06-23 2006-06-23 Use of an anti c5 complement antibody to treat patients with sickle cell disease

Country Status (1)

Country Link
WO (1) WO2007002571A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080110800A (en) 2006-03-15 2008-12-19 알렉시온 파마슈티칼스, 인코포레이티드 Treatment of patients with paroxysmal nocturnal hematuria with complement inhibitor
EP2894166A1 (en) * 2008-11-10 2015-07-15 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
IT201600121482A1 (en) * 2016-11-30 2018-05-30 Univ Degli Studi Di Verona Factor H for use in the treatment and / or prevention of the formation of heterotrombi in patients with sickle cell disease
WO2023023220A1 (en) * 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HILLMEN P ET AL: "EFFECT OF ECULIZUMAB ON HEMOLYSIS AND TRANSFUSION REQUIREMENTS IN PATIENTS WITH PAROXYSMAL NOCTRURNAL HEMAGLOBINURIA", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 350, no. 6, 5 February 2004 (2004-02-05), pages 552 - 559, XP009057948, ISSN: 1533-4406 *
MOLD CAROLYN ET AL: "Complement activation during painful crisis in sickle cell anemia", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 76, no. 3 PART 1, 1995, pages 314 - 320, XP008073565, ISSN: 0090-1229 *
TEST SAMUEL T ET AL: "Defective regulation of complement by the sickle erythrocyte: Evidence for a defect in control of membrane attack complex formation", BLOOD, vol. 83, no. 3, 1994, pages 842 - 852, XP008073566, ISSN: 0006-4971 *
YAZDANBAKHSH KARINA: "Controlling the complement system for prevention of red cell destruction.", CURRENT OPINION IN HEMATOLOGY. MAR 2005, vol. 12, no. 2, March 2005 (2005-03-01), pages 117 - 122, XP008073571, ISSN: 1065-6251 *
YAZDANBAKHSH KARINA: "Development of complement therapeutics for inhibition of immune-mediated red cell destruction", TRANSFUSION (MALDEN), vol. 45, no. 2, Suppl. S, August 2005 (2005-08-01), pages 122S - 129S, XP008073567, ISSN: 0041-1132 *

Also Published As

Publication number Publication date
WO2007002571A2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
WO2007117600A3 (en) Combination therapy for treating autoimmune diseases
WO2005034843A3 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
WO2014205555A8 (en) Methods and uses for diagnosis and treatment of prostate cancer
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
WO2007089454A3 (en) Methods for enhancing skin treatments
EP3447491A3 (en) Diagnosis and treatments relating to th2 inhibition
EA200901211A1 (en) ANTIGENS OF C5 PROTEIN AND THEIR APPLICATION
WO2008150490A3 (en) Uses and compositions for treatment of psoriasis and crohn's disease
WO2005107730A3 (en) Cysteamines for treating complications of hypercholesterolemia and diabetes
BRPI0818191A2 (en) methods for the formation of vessels from a placental perfusate cell population and for the treatment of an individual having a heart or vascular disease, disorder, condition or insulin
WO2007053661A3 (en) Uses of anti-cd40 antibodies
EA201001695A1 (en) APPLICATION OF EPOTHILON D FOR THE TREATMENT OF DISEASES ASSOCIATED WITH TAU-PROTEIN
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
WO2007089945A3 (en) Treating diseases by targeting silt3
WO2009068659A3 (en) Novel disease treatment by predicting drug association
WO2008157787A3 (en) Hydroxylated tolans and related compounds in the treatment of cancer
WO2005020903A3 (en) Methods of improving the safety of zonisamide therapy
WO2010064248A3 (en) Methods of diagnosing and treating motor neuron diseases
WO2010115034A3 (en) Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention
WO2003099105A3 (en) Diagnosis and treatment of human dormancy syndrome
WO2006009919A3 (en) Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods
WO2009027703A3 (en) Identifying organ damage
WO2007002571A3 (en) Use of an anti c5 complement antibody to treat patients with sickle cell disease
WO2007117589A3 (en) Enhanced fc receptor-mediated tumor necrosis factor superfamily and chemokine mrna expression in peripheral blood leukocytes in patients with rheumatoid arthritis
WO2008009868A3 (en) Methods and tools for the therapy of neurodegenerative pathologies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06785565

Country of ref document: EP

Kind code of ref document: A2